Journal of Chromatography B, Journal Year: 2024, Volume and Issue: 1252, P. 124445 - 124445
Published: Dec. 28, 2024
Language: Английский
Journal of Chromatography B, Journal Year: 2024, Volume and Issue: 1252, P. 124445 - 124445
Published: Dec. 28, 2024
Language: Английский
International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 142852 - 142852
Published: April 1, 2025
Language: Английский
Citations
0Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)
Published: April 7, 2025
Ulcerative colitis (UC) poses significant threats to human health and quality of life worldwide, as it is a chronic inflammatory bowel disease. 3'-sialyllactose (3'-SL) key functional component milk oligosaccharides. This study systematically evaluates the prebiotic effects 3'-SL its therapeutic potential in combination with Bifidobacterium infantis (B. infantis) for UC. The findings reveal that B. synergistically mitigate intestinal inflammation barrier dysfunction by promoting production short-chain fatty acids (SCFAs) through cross-feeding mechanisms among gut microbiota. Individually, 3'-SL, infantis, synbiotic treatment all effectively alleviated UC symptoms, including reduced weight loss, improved disease activity scores, prevention colon shortening. Histopathological immunofluorescence analyses further demonstrated significantly ameliorated colonic injury, enhanced function, restored goblet cell counts, increased glycoprotein content crypt cells, upregulated expression tight junction proteins (ZO-1, occludin, claudin-1). Notably, outperformed individual components better restoring microbiota balance, elevating SCFA levels, modulating serum cytokine profiles, thereby reducing inflammation. These provide mechanistic insights into protective underscore other disorders.
Language: Английский
Citations
0Food Bioscience, Journal Year: 2025, Volume and Issue: 68, P. 106651 - 106651
Published: April 22, 2025
Language: Английский
Citations
0Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: Oct. 28, 2024
Background Clinical observations have recently shown that Abelmoschus manihot (L.) in the form of Huangkui capsule (HKC) and combination with irbesartan (EB) is an effective therapy for diabetic nephropathy (DN) patients type 2 diabetes (T2D). The present study aims to explore mechanisms underlying therapeutic efficacies HKC its EB DN via gut-kidney axis. Methods HKC, EB, their or vehicle were administered db/db mice, which animal model T2D DN. Comparative analyses gut microbiota, serum metabolites, kidney transcriptomics before after drug administration performed. Results After treatment 4 weeks, urinary albumin-to-creatinine ratios decreased significantly mice In terms abundances Faecalitalea, Blautia, Streptococcus increased but those Bacteroidetes, Firmicutes, Enterobacteriaceae, Desulfovibrio decreased. Parallelly, mainly including quercetin 3′-glucuronide L-dopa, elevated while cortisol cytochalasin B reduced. Furthermore, S100a8 , S100a9 Trem1 Mmp7 genes kidneys downregulated. These altered elements associated proteinuria/albuminuria reduction. However, had no effects on changes blood pressure specific differentially expressed kidneys. Conclusion provides experimental evidence regulates circulating renal gene activities, are useful better understanding action A. through
Language: Английский
Citations
0Journal of Chromatography B, Journal Year: 2024, Volume and Issue: 1252, P. 124445 - 124445
Published: Dec. 28, 2024
Language: Английский
Citations
0